Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
Saved in:
| Title: | Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. |
|---|---|
| Authors: | Fisher SS; RTI International, Durham, North Carolina, United States of America., Lindaas A; Acumen LLC, Burlingame, California, United States of America., Muthuri SG; IBM Consulting, Bethesda, Maryland, United States of America., Lloyd PC; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Gruber JF; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Richey MM; RTI Health Solutions, Durham, North Carolina, United States of America., Lyu H; Acumen LLC, Burlingame, California, United States of America., Cheng AS; Acumen LLC, Burlingame, California, United States of America., Kowarski LS; IBM Consulting, Bethesda, Maryland, United States of America., McKillop MM; IBM Consulting, Bethesda, Maryland, United States of America., Bui C; RTI Health Solutions, Durham, North Carolina, United States of America., Clarke TC; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Beers J; IBM Consulting, Bethesda, Maryland, United States of America., Burrell T; IBM Consulting, Bethesda, Maryland, United States of America., Duenas PF; Acumen LLC, Burlingame, California, United States of America., Chen Y; Acumen LLC, Burlingame, California, United States of America., Sheng M; IBM Consulting, Bethesda, Maryland, United States of America., Forshee RA; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Anderson SA; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Chillarige Y; Acumen LLC, Burlingame, California, United States of America., Anthony MS; RTI Health Solutions, Durham, North Carolina, United States of America., Shoaibi A; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Layton JB; RTI Health Solutions, Durham, North Carolina, United States of America. |
| Source: | PloS one [PLoS One] 2025 Nov 24; Vol. 20 (11), pp. e0333704. Date of Electronic Publication: 2025 Nov 24 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0333704 |
